Patients with non-Hodgkin's B-cell lymphoma who received an antitumor vaccine of idiotypic Ig protein showed humoral and proliferative immune responses. Because immunity to some antigens, including tumor antigens and human pathogenic viruses, may be better correlated with the cytolytic cellular immune response, we evaluated 16 non-Hodgkin's lymphoma patients immunized with autologous idiotypic Ig molecules for changes in tumor-specific cytotoxic T-lymphocyte precursor (CTLp) frequency using limiting dilution analysis. Eleven patients had a significant increase in tumor-specific CTLp. Eight of these 11 patients remain without evidence of dis-HE IMMUNOGLOBULIN (Ig) idiotype on the surface T of B-cell lymphomas can serve as a tumor-specific antigen against which to target therapy.'.'' Each Ig molecule expresses relatively unique "variable" regions, and most Bcell lymphomas express such idiotypic determinants on their cell surface. Some patients with B-cell lymphomas undergoing passive immunotherapy with specific antiidiotypic antibodies have experienced long-term remissions.'-4 This approach is limited, however, by the requirements to customize individual antibodies for each patient. In addition, in some cases, the tumors initially regressed, but cells bearing Igs with mutations or with modulated surface Ig escaped and
sponses, antiidiotype antibodies, and T-cell proliferative responses to tumor idiotypic Ig in vitro, respectively.'-* Although the immunologic evaluation of tumor antigen vaccines has focused on the humoral or delayed type hypersensitivity response, there is considerable evidence that cytotoxic T lymphocytes (CTL) may also actively contribute to tumor rejection.'2-3" Additionally, we previously showed that tumor-specific CTL can be grown ex vivo from such patients with B-cell lymphoma^.^',^' In this study, we evaluated the tumor-specific CTL response to Ig idiotype vaccine in patients with nomHodgkin's B-cell lymphoma.
was used as a target for natural killer activity. Long-term CTL lines were established as modified only by the use of irradiated, cryopreserved, tumor cells that had been in culture for less than 10 days in place of irradiated tumor cell lines as stimulators. All non-CTL lines and limiting dilution assays were maintained in RPMI 1640 (ICN Biomedicals Inc, Costa Mesa, CA) supplemented with 10% FCS, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 pg/mL streptomycin (Irvington Scientific, Santa Ana, CA). CTL lines were maintained in the media described above with the addition of 10% T-lymphocyte-conditioned media.36
Determination of cytotoxic T-lymphocyte precursor (CTLp) frequency. Tumor specimens were thawed, placed into culture, and evaluated on days 3 through 7 post-thaw for "Cr labeling as described." For each patient, an aliquot of each frozen PBL sample was thawed and placed into limiting dilution culture in 96-well plates at concentrations from 10,000 to 500,000 PBUwell with 5,000 irradiated (10,000 cGy) autologous tumor stimulators as de~cribed.~' After 6 days of culture, each well was assayed for cytolytic activity against 51Cr-labeled autologous tumor and control targets in a 4-hour chromium release assay.36 Autologous EBV-LCL, K562, or an isotype and histology matched unrelated non-Hodgkin's lymphoma were used as control targets. Wells in which lysis of targets was greater than or equal to 10% above spontaneous release were considered positive. The CTLp frequency was calculated by the technique of Fazekas de St Groth." When sufficient prevaccine PBL were available, time points were divided into two individual assays.
Monoclonal antibodies and jluorescence-activated cell sorter (FACS) analysis. The following monoclonal antibodies were used in these studies: OKT3 and OKT8 (Ortho, Raritan, NJ); anti-CD4, anti-TCRG-I, anti-TCR a/@, (Becton Dickinson, Oxnard, CA); anti-CDI la, anti-CD18 (LFA-1) (TS1.18, TSl.22)36; anti-major histocompatibility complex (MHC) class I (PA2.6), anti-MHC class I1 (L243),'9 antihuman Ig, anti-K or -y light chain; fluoroscein isothiocyanate-conjugated F(ab)2 goat antimouse whole Ig; and isotype matched irrelevant mouse Ig (Caltag, S San Francisco, CA). Cell surface expression of molecules binding these antibodies was evaluated on FACScan (Becton Dickinson).
Standard 4-hour chromium release assays were performed using long-term CTL lines as effeck" Target cells included autologous lymphoma, irrelevant lymphoma, autologous EBV-LCL, and K562. Specific lysis was calculated as [experimental release -spontaneous releadtotal release -spontaneous release] X 100. Antibody inhibition assays were performed with the antibody present throughout the standard CTL assay, and percent inhibition was determined as follows: 1 -(experimental specific cytolysidcontrol specific cytolysis) x Statistical evaluation. Patient assays were performed in a blinded fashion with respect to clinical response and course. CTL frequencies for each time point were calculated by the technique of Fazekas de St Groth3* and evaluated using the x2 test for fit to the Poisson distribution!' Changes in CTLp frequency were considered significant only if 95% confidence intervals were nonoverlapping. Correlation of clinical course and maximal change in CTLp frequency was performed with CTLp as a dichotomous variable using the two-tailed Fisher Exact t-test to evaluate statistical significance?' Nondichotomous variables were evaluated by the Wilcoxon Test !' These statistical tests were performed using 4th Dimension V I .0.6 (ACI US Inc, Cupertino, CA) and Instat v2.0 (Graph Pad Software, San Diego, CA) on Apple MacIntosh computers. Kaplan-Meier plots43 were developed using institutional software kindly provided by S Brain (Stanford University, Stanford, CA) with statistical significance derived by log-rank evaluation."
RESULTS
Clinical and demographic characteristics of the 16 patients are summarized in Table 1 .
Cell spec$city panels and antibo& inhibition assays.
Patient characteristics.
These patients are representative of the population of nonHodgkin's lymphoma patients enrolled in our clinical trial.' There are six men and 10 women ranging from 23 to 59 years of age at the time of diagnosis. Patient 24 had stage IIA disease, and all remaining patients had either stage IIIA or IVA disease. Eleven patients were in a clinical complete response, and 5 patients had minimal disease present at the time of vaccination. Treatment regimens were diverse ( Table 2 .
CTLp frequencies were determined using each individual's tumor and a control tumor or cell line as targets. Prevaccine values, maximal response, 95% confidence intervals, magnitude of response over prevaccine values, and time to maximal response for both tumor and control targets are summarized in Table 3 . Prevaccine antitumor CTLp frequencies range from 0.3/106 to 2.1/106 PBL. Control targets consisted of autologous EBV-LCL for five patients; isotype, light chain, and histology matched unrelated tumor controls for two patients, and K562 (NK target) for nine patients. Neither patient with matched tumor controls demonstrated cytolytic activity to the unrelated tumor targets. Limited responses were evident with autologous EBV-LCL controls. The initial EBV-LCL CTLp response of patient 14 was the maximal value detected but was undetectable until week 6, and subsequent CTLp frequency ranged from 0.1/106 to 0.3/106 PBL. Patient 21 had an increase in autologous EBV-LCL CTLp frequency from undetectable in early samples to 0.1/106 PBL at 11 weeks and reached a maximum at 54 weeks of 4.1/106 PBL. The kinetics of this response were dramatically different from the antitumor response that reached its maximum at 8 weeks (Table 3 ). These two EBV-LCL responses were discordant with the antitumor CTLp responses. In contrast, patient 26 had a concordant increase in autologous EBV-LCL CTLp, providing evidence for lack of a tumor-specific CTLp response. Patient 25 demonstrated a concordant antitumor CTLp response and a cytolytic precursor response to K562, suggesting that the antitumor CTLp was due to natural killer cell activity. Patient 34, although demonstrating a 5.3-fold increase in tumor-specific CTLp, displayed overlapping 95% confidence intervals. This response was, therefore, considered not significant. The magnitude of the tumor-specific CTLp response with respect to disease status is plotted in Fig 1. For subsequent statistical evaluation, we established a threshold value of fivefold or greater increase in tumor-
CTLp frequencies.
For personal use only. on April 30, 2017. by guest www.bloodjournal.org From International working formulation nomenclature is used for patients histologic diagnosis33 and clinical staging is per Ann Arbor staging system." Duration of disease is the period from diagnosis to initiation of vaccination.
Abbreviations: FSC, follicular small cleaved cell lymphoma; FLC, follicular large cell lympphoma; FM, follicular mixed small and large cell lymphoma; DLC. diffuse large cell lymphoma; NED, no evidence of disease; CVP, cyclophosphamide. vincristine, prednisone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; BCEPP, bleomycin, cyclophosphamide, VP-16, procarbazine, prednisone; ABMT, autologous bone marrow transplantation; BAEP, bleomycin, adriamycin, VP-16, prednisone; DHAP, cisplatin. Ara-C, dexamethasone; pC-P, chlorambucil and Drednisone (5-day pulse); pChl, chlorambucil (Bday pulsel; pP, prednisone 15-day pulse); dChl. chlorambucil daily; AWD, alive with disease; DOD, dead of disease. specific CTLp frequency over prevaccine values as a significant change.
A greater than fivefold increase in tumor-specific CTLp correlates with the likelihood of progression free survival as a dichotomous variable with P = .0256 (Table 2) . KaplanMeier analysis demonstrated a significant (P = .002) correlation of freedom from progression with an increased tumorspecific CTLp response (Fig 2) . Exclusion of the two patients treated with bone marrow transplantation or inclusion of all tumor-specific responding patients in the Kaplan-Meier analysis maintained statistical significance. Individual patients demonstrated different patterns of CTLp responses. Two patients (nos. 22 and 32) showed steady increases in the tumor-specific CTLp well beyond the termination of the vaccination protocol (patient 22; Fig 3A) . This increase was sustained more than 80 weeks postvaccination (data not shown). The most common pattern consisted of a maximal response at 24 to 35 weeks with a return to baseline by approximately 39 to 46 weeks after initiation of the vaccine procedure (Fig 3B, C, and D) . The nonspecific response for patient 25 (Fig 3B and C) and the insignificant response of patient 34 are also shown (Fig 3D) .
Cytolytic T-cell lines were established and sustained in culture for periods ranging from 24 to 36 weeks from patients 14, 19, 21, 22, and 24. All of these lines were tumor-specific; cytolytic (Fig 4) ; and CD3'.
Generation of CTL lines.
For 
CD8+, CD4-, alp T-cell receptor (TCR)+ by FACS analysis (Fig 5). Recognition of tumor was MHC class I restricted as demonstrated by antibody inhibition in standard chromium
release assays (Fig 6) . In no case were the CTL MHC unrestricted or $6 TCR+.32,46
DISCUSSION
Although vaccination is a proven approach for prophylaxis against numerous infectious agents,'" its utility for tumor immunotherapy is still under investigation. For personal use only. on April 30, 2017. by guest www.bloodjournal.org From regression77 require large numbers of patients with extensive follow-up for definitive conclusions regarding efficacy of any immunotherapy. Immunologic responses are candidate surrogate end points that can guide development of immunotherapies. We have previously documented that patients with B-cell lymphoma can be induced to make humoral and proliferative responses to the idiotype on their t~m o r .~,~ We recently reported that such immune responses were strongly correlated with freedom from progression of disease.8 The present report shows that CTL precursors are also induced by vaccination and they too show a strong correlation with freedom from progression. The significant correlation of an increase in tumor-specific CTLp and freedom from progression reported here provides additional evidence that vaccination with protein antigens can induce CTL immune reand supports the role of CTL in the antitumor immune response.
Vaccination with idiotypic Ig and immunologic adjuvant attempts to induce a response to a "self-antigen." This immunization may elicit highly specific immune responses or nonspecific responses, including natural killer activity, shared B-cell reactivity, or unexpected tumor cell reactivity.
sponses 15.59-61 69.14-76
Therefore, several target cell controls were possible for these studies with each one evaluating different aspects of immune reactivity. Limited by the numbers of PBL for each patient at each time point, we elected to test only one "alternative" (control) target cell for each patient. Selection of the most appropriate control target cell is not obvious and was performed randomly. We included natural killer cell targets (K562) (9 patients); autologous nontumor B cells (EBV-LCL) (5 patients); and unrelated, histology, and isotype matched non-Hodgkin's lymphomas (2 patients). The response to EBV-LCL is complicated by the endogenous anti-EBV cytolytic immune response (both CTL and natural killer),78 which varies with reactivation status of latent EBV infection that is present in the vast majority of adults in this country. Unrelated but histology and isotype matched lymphoma targets may lack critical HLA alleles or express different populations of accessory molecules. We were, as expected, able to demonstrate natural killer (3 patients), EBV-LCL cytolytic (3 patients), and tumor (15 patients) reactivity in patients undergoing this vaccination procedure. However, only increases in tumor-specific responses correlate with freedom from progression. The patterns of responses seen in this set of patients is of significant interest. Our calculated CTLp frequencies may be an underestimation of the true frequency because we elected not to add T-cell growth factors to the limiting dilution cultures to minimize the generation and amplification of nonspecific (natural killer) cytolytic activity. Nevertheless, patient 25 demonstrated natural killer and antitumor activity similar to that reported by other gro~ps.'~ Of note, this patient developed progressive disease as did patient 26, who also had a nonspecific increase in cytolytic activity. The absence of cytolytic activity toward the two irrelevant matched tumor controls (patients 15 and 16) and the majority of autologous EBV-LCLs suggests that the tumor-specific responses measured are tumor antigen specific. This conclusion is supported by the tumor specificity of the long-term CTL lines established from five of these patients along with previously reported long-term CTL line^."^^*.^.^' It is of note that patients 22 and 32 have sustained increases in tumor-specific CTLp and remain free from progressive disease. Khazaie et ala suggest that sustained antitumor immune responses may be due to "dormant" tumor cells that provide continued antigenic stimulation. The long-term maintenance of antitumor immune responses in these two patients, as demonstrated by persistent elevations of tumor-specific CTLp, may be a result of such low-grade antigenic stimulation due to minute and undetectable tumor. The persistent immune response may, in turn, maintain the tumor load at an undetect- Using this technique of expansion, they calculated tumor-specific CTLp frequencies comparable with alloreactive CTLp frequencies in seven patients but did not report clinical correlation. Mazzocchi et alX2 performed similar experiments expanding PBL for several weeks before examining cytolytic precursors for both CTL and natural killer cells in peripheral blood and tumor invaded lymph nodes. They showed that there was no difference in CTLp frequency between PBL and tumor-invaded lymph nodes in six of nine patients, a higher CTLp frequency in tumor-invaded lymph nodes in two of nine patients, and higher CTLp frequency in PBL in one of nine patients. This group did not report clinical correlation with these CTLp frequencies. It is not possible to compare the numerical values for CTLp frequencies reported in our study, using traditional limiting dilution analysis on PBL, with those of Coulie or Mazzocchi given the expansion phases used by both. Additionally, we previously showed for non-Hodgkin's lymphomas that tumor-specific CTL can be generated within a 4-week interval from autologous or naive donor peripheral blood mononuclear cells.'" Mitchell et a183,84 evaluated the induction of CTL precursors that recognize allogeneic tumor cells, the source of the antimelanoma vaccine, in a fashion similar to that which we used. They demonstrated a correlation of these CTL precursors with patient's clinical course For personal use only. on April 30, 2017. by guest www.bloodjournal.org From and showed that, in some cases, established allogeneic CTL lines could kill autologous melanoma cells. Our study, however, is the first human study to both directly evaluate changes in autologous tumor-specific CTLp frequency induced during an immunomodulatory therapy and correlate these changes with patient's clinical course.
We determined that idiotypic Ig vaccination can elicit changes in tumor-specific CTLp frequency and that these changes show a significant correlation with clinical course. Our study suggests that evaluation of changes in the CTL compartment can be important in the assessment of patients undergoing immunomodulatory therapies. Such evaluation may provide insight into the nature of tumor-associated antigens and the relative efficacy of various vaccines. Our findings suggest that new vaccine strategies, including cytokineaugmented cellular, protein, peptide, and/or polynucleotide (naked DNA) vaccination, which optimize the development of antigen-specific CTL responses, may result in improved clinical outcomes.
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